Proteomics for cancer drug design.

Expert Rev Proteomics 2019 Aug 4;16(8):647-664. Epub 2019 Aug 4.

Center for Applied Proteomics and Molecular Medicine, George Mason University , Manassas , VA , USA.

: Signal transduction cascades drive cellular proliferation, apoptosis, immune, and survival pathways. Proteins have emerged as actionable drug targets because they are often dysregulated in cancer, due to underlying genetic mutations, or dysregulated signaling pathways. Cancer drug development relies on proteomic technologies to identify potential biomarkers, mechanisms-of-action, and to identify protein binding hot spots. : Brief summaries of proteomic technologies for drug discovery include mass spectrometry, reverse phase protein arrays, chemoproteomics, and fragment based screening. Protein-protein interface mapping is presented as a promising method for peptide therapeutic development. The topic of biosimilar therapeutics is presented as an opportunity to apply proteomic technologies to this new class of cancer drug. : Proteomic technologies are indispensable for drug discovery. A suite of technologies including mass spectrometry, reverse phase protein arrays, and protein-protein interaction mapping provide complimentary information for drug development. These assays have matured into well controlled, robust technologies. Recent regulatory approval of biosimilar therapeutics provides another opportunity to decipher the molecular nuances of their unique mechanisms of action. The ability to identify previously hidden protein hot spots is expanding the gamut of potential drug targets. Proteomic profiling permits lead compound evaluation beyond the one drug, one target paradigm.

Download full-text PDF

Source
http://dx.doi.org/10.1080/14789450.2019.1650025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736641PMC
August 2019
2 Reads

Publication Analysis

Top Keywords

proteomic technologies
16
cancer drug
12
drug
9
drug development
8
biosimilar therapeutics
8
hot spots
8
drug targets
8
protein arrays
8
phase protein
8
spectrometry reverse
8
drug discovery
8
reverse phase
8
mass spectrometry
8
technologies
6
proteomic
5
apply proteomic
4
technologies class
4
class cancer
4
suite technologies
4
technologies including
4

References

(Supplied by CrossRef)

Sun J et al.
BMC Syst Biol [Internet] 2017

Bhatt V et al.
Am J Manag Care 2018

Similar Publications